Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.

被引：1
|
作者：
Rescigno, Pasquale
Boysen, Gunther
Rodrigues, Daniel Nava
Seed, George
Dolling, David
Riisnaes, Ruth
Crespo, Mateus
Bianchini, Diletta
Sumanasuriya, Semini
Figueiredo, Ines
Christova, Rossitza
Gil, Veronica
Goodall, Jane
Sharp, Adam
Rubin, Mark A.
Yuan, Wei
Barbieri, Christopher
Mateo, Joaquin
Carreira, Suzanne
De Bono, Johann S.
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Inst Canc Res, Clin Trials & Stat Unit, London, England
[4] Univ Bern, Bern, Switzerland
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical implications of PTEN loss in prostate cancer
    Tamara Jamaspishvili
    David M. Berman
    Ashley E. Ross
    Howard I. Scher
    Angelo M. De Marzo
    Jeremy A. Squire
    Tamara L. Lotan
    Nature Reviews Urology, 2018, 15 : 222 - 234
  • [42] Clinical implications of PTEN loss in prostate cancer
    Jamaspishvili, Tamara
    Berman, David M.
    Ross, Ashley E.
    Scher, Howard I.
    De Marzo, Angelo M.
    Squire, Jeremy A.
    Lotan, Tamara L.
    NATURE REVIEWS UROLOGY, 2018, 15 (04) : 222 - 234
  • [43] Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment, in PTEN-Deficient Prostate Cancer
    Zhao, Di
    Cai, Li
    Lu, Xin
    Liang, Xin
    Li, Jiexi
    Chen, Peiwen
    Ittmann, Michael
    Shang, Xiaoying
    Jiang, Shan
    Li, Haoyan
    Meng, Chenling
    Flores, Ivonne
    Song, Jian H.
    Horner, James W.
    Lan, Zhengdao
    Wu, Chang-Jiun
    Li, Jun
    Chang, Qing
    Chen, Ko-Chien
    Wang, Guocan
    Deng, Pingna
    Spring, Denise J.
    Wang, Y. Alan
    DePinho, Ronald A.
    CANCER DISCOVERY, 2020, 10 (09) : 1374 - 1387
  • [44] CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer
    Burkhardt, Lia
    Fuchs, Sarah
    Krohn, Antje
    Masser, Sawinee
    Mader, Malte
    Kluth, Martina
    Bachmann, Frederik
    Huland, Hartwig
    Steuber, Thomas
    Graefen, Markus
    Schlomm, Thorsten
    Minner, Sarah
    Sauter, Guido
    Sirma, Hueseyin
    Simon, Ronald
    CANCER RESEARCH, 2013, 73 (09) : 2795 - 2805
  • [45] Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer.
    Santos, Giordano Fabricio Cittolin
    Prophet, Malshundria
    Gourdin, Theodore Stewart
    Drusbosky, Leylah
    Ledet, Elisa Marie
    Sartor, A. Oliver
    Sonpavde, Guru
    Lilly, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
    Shenoy, T. R.
    Boysen, G.
    Wang, M. Y.
    Xu, Q. Z.
    Guo, W.
    Koh, F. M.
    Wang, C.
    Zhang, L. Z.
    Wang, Y.
    Gil, V.
    Aziz, S.
    Christova, R.
    Rodrigues, D. N.
    Crespo, M.
    Rescigno, P.
    Tunariu, N.
    Riisnaes, R.
    Zafeiriou, Z.
    Flohr, P.
    Yuan, W.
    Knight, E.
    Swain, A.
    Ramalho-Santos, M.
    Xu, D. Y.
    de Bono, J.
    Wu, H.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1495 - 1507
  • [47] Combined neuroendocrine differentiation and androgen receptor hyperactivity in MAP37 and CHD1 null prostate cancer
    Rider, Leah C.
    Rodrigues, Lindsey U.
    Karimpour-Fard, Anis
    Romero, Lina
    Gillette, Claire
    Costello, James C.
    Cramer, Scott D.
    CANCER RESEARCH, 2017, 77
  • [48] Clinical implications of advanced molecular cytogenetics in cancer
    Mundle, SD
    Sokolova, I
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (01) : 71 - 81
  • [49] CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo
    Oh-Hohenhorst, Su Jung
    Tilki, Derya
    Ahlers, Ann-Kristin
    Suling, Anna
    Hahn, Oliver
    Tennstedt, Pierre
    Matuszcak, Christiane
    Maar, Hanna
    Labitzky, Vera
    Hanika, Sandra
    Starzonek, Sarah
    Baumgart, Simon
    Johnsen, Steven A.
    Kluth, Martina
    Sirma, Hueseyin
    Simon, Ronald
    Sauter, Guido
    Huland, Hartwig
    Schumacher, Udo
    Lange, Tobias
    CANCER GENE THERAPY, 2022, 29 (01) : 49 - 61
  • [50] Clinical implications of homologous recombination repair mutations in prostate cancer
    Cresta Morgado, Pablo
    Mateo, Joaquin
    PROSTATE, 2022, 82 : S45 - S59
12345